Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension

Pulmonary Circulation

Volumn 1, Issue 2, 2011, Pages 244-249

  Soon, Elaine ^a,b   Doughty, Natalie J ^a   Treacy, Carmen M ^a   Ross, Robert M ^a   Toshner, Mark ^a   Upton, Paul D ^a   Sheares, Karen ^a   Morrell, Nicholas W ^b   Pepke Zaba, Joanna ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

6 minute walk distance; Biomarker; N terminal pro B type natriuretic peptide

Indexed keywords

EID: 85009714990     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.83450     Document Type: Article

References (29)

1. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-70.
2. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S-92.
3. Gardner RS, Ozalp F, Murday AJ, Robbs SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
4. Bayes-Genis A, Pascual-Figal DA, Fabregat J, Domingo M, Planas F, Casas T, et al. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol 2007;120:338-43.
5. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicolls MG, Richards AM. Treatment of heart failure guided by amino-terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
6. Pascual-Figal DA, Domingo M, Casas T, Gich I, Ordonez-Llanos J, Martinez P, et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008;29:1011-8.
7. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006;129:1313-21.
8. Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007;29:737-44.
9. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525-9.
10. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-70.
11. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in primary pulmonary hypertension. Circulation 2000;102:865-70.
12. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary hypertension. Eur Heart J 2006;27:1485-94.
13. Park MH, Scott RL, Uber PA, Ventura HO, Mehra MR. Usefulness of B-type natriuretic peptide as a predictor of treatment outcomes in pulmonary arterial hypertension. Congest Heart Fail 2008;10:221-5.
14. Mackay LS, Hughes R, Peaston R, MacGowan G, Parry G, Fisher AJ, et al. Serial NT-probrain natriuretic peptide levels in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007;26:S248.
15. Schou M, Gustafsson F, Kjaer A, Hildebrandt P. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 2007;28:177-82.
16. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simmoneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-95.
17. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2006;353:2148-57.
18. Olschewski H, Simonneau G, Galiè N, Higgenbottam T, Naeije R, Rubin LJ, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
19. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-301.
20. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005;46:118-23.
21. Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, et al. Anaemia and renal failure are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007;9:787-94.
22. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993;39: 561-77.
23. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol 2002;40:780-8.
24. Macchia A, Marchioli R, Marfisi RM, Scarano M, Levantesi G, Tavazzi L, et al. A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-47.
25. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomised controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
26. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
27. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647-52.
28. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
29. Carlin C, Blyth KG, McLure LE, Spooner R, Peacock AJ, Johnson MK. Serial NT-proBNP measurements predict early clinical worsening and mortality in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Thorax 2008;63:A44.